温州康寧醫院股份有限公司

Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the Peo)

Stock cod

2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

	For the year ended December 31, 2022 **(RMB'000)**	2021 ([illegible]B'000) ([illegible])
[illegible]		
[illegible]	**1,484,903**	1,297,430
[illegible]	**15,605**	95,691
I[illegible]	**26,574**	54,831
[illegible]	**-10,969**	40,860
[illegible] C[illegible]	**-24,221**	44,036
[illegible]	**13,252**	-3,176

	As of December 31, 2022 **(RMB'000)**	A[illegible]f D[illegible]31, 2021 ([illegible]B'000) ([illegible])	A[illegible]f J[illegible]1, 2021 ([illegible]B'000) ([illegible])
[illegible]	**2,637,787**	2,377,955	2,161,262
[illegible]	**1,311,885**	1,097,676	946,349
[illegible]	**1,325,903**	1,280,279	1,214,913
E[illegible] f C[illegible]	**1,201,585**	1,208,264	1,122,248
[illegible]	**124,318**	72,015	92,635

	For the year ended December 31, 2022 **(RMB'000)**	2021 ([illegible] B'000)
[illegible]	**227,221**	193,896
[illegible]	**-273,615**	-239,049
[illegible]	**116,178**	33,833
[illegible]	**69,861**	-11,358

3 BUSINESS REVIEW AND OUTLOOK

3.1 Business Review

[illegible]

[illegible]

[illegible]

G f f f f ff , f f f f f f . I 2022, G 1,107 f 12,172 , f 3.266 . I , f , G f - f f- f , G , C ID-19 C ID-19 f f , f C ID-19 , .

I 2022, G f f G f G ' f , f f , f G .

3.2 Business Highlights

I 2022, G ' I. . , G , J H f f H E H - &D C 2022. A f D 31, 2022, f 42 f 3 . , G f - f - , I H + , f , , , ff .

I 2022, G f f C , f C C f D B f C C f D f f - f F f C . G , f I C B f D A D D f f f . A , G f f I (- f-I A), L G (D ADHD D), L , K , f f f f f .

4 MANAGEMENT DISCUSSION AND ANALYSIS

4.1 Financial Review

[illegible] B1,484.9 [illegible] 14.4% [illegible] 2021. [illegible] B1,366.8 [illegible] 13.6% [illegible] 2021. [illegible] 23.9% (2021: 25.4%). [illegible] B352.9 [illegible] 7.3% [illegible] 2021. [illegible] B-24.2 [illegible] 2022. [illegible] B41.1 [illegible] B227.2 [illegible] (2021: [illegible] B193.9 [illegible]), [illegible] 17.2% [illegible] 2021.

4.1.1 Revenue and Cost of Revenue

[illegible]: ([illegible]) [illegible]; ([illegible]) [illegible]; ([illegible]) [illegible].

[illegible]:

	For the year ended December 31,	
	2022	2021
	(RMB'000)	*([illegible]B'000)*
[illegible]	**1,366,817**	1,202,774
[illegible]	**110,018**	71,097
[illegible]	**8,068**	23,559
Total revenue	**1,484,903**	1,297,430

[illegible]

[illegible] (**Billing Revenue**) [illegible]

[illegible]

	For the year ended December 31,	
	2022	2021
	(RMB'000)	*([illegible]B'000)*
B[illegible]	**1,425,005**	1,229,996
L[illegible]: [illegible]	**43,545**	-18
[illegible][1]	**14,643**	27,240
[illegible]	**1,366,817**	1,202,774

[illegible]:

(1) L[illegible] G[illegible] (**Patients in Need**) [illegible]

F[illegible] G[illegible]' B[illegible] [illegible]B1,425.0 [illegible], 15.9% [illegible] 2021, [illegible]. D[illegible] [illegible]B43.5 [illegible] 2021. [illegible] G[illegible] 2023. D[illegible] [illegible]B14.6 [illegible] [illegible]B12.6 [illegible] 2021, [illegible].

[illegible] B[illegible], [illegible] G[illegible]'[illegible]:

	For the year ended December 31,	
	2022	2021
	(RMB'000)	*([illegible]B'000)*
Treatment and general healthcare services		
B[illegible]	**1,119,887**	962,408
C[illegible]	**770,287**	658,194
G[illegible]	**349,600**	304,214
Pharmaceutical sales		
B[illegible]	**305,118**	267,588
C[illegible]	**269,828**	238,918
G[illegible]	**35,290**	28,670
Billing Revenue from owned hospitals	**1,425,005**	1,229,996
C[illegible]	**1,040,115**	897,112
G[illegible]	**384,890**	332,884

D[illegible], B[illegible] G[illegible] [illegible] B1,425.0 [illegible] B195.0 [illegible] 2021, [illegible] B[illegible] K[illegible] H[illegible], [illegible] K[illegible] H[illegible], [illegible] K[illegible] H[illegible], [illegible] K[illegible] H[illegible], [illegible] C[illegible] H[illegible] C[illegible] H[illegible] [illegible] H[illegible] J[illegible] H[illegible], [illegible] D[illegible], [illegible] G[illegible]'[illegible] B[illegible] 15.6% [illegible] 2021, [illegible].

[illegible] B[illegible] G[illegible] [illegible]:

	For the year ended December 31, 2022	2021
Inpatients		
I[illegible]	**9,688**	8,728
Eff[illegible]	**3,536,120**	3,185,720
[illegible] *(%)*	**88.7**	87.1
[illegible]	**3,134,950**	2,773,964
[illegible] *(B'000)*	**1,061,798**	908,337
A[illegible] *(B)*	**339**	327
[illegible] *(B'000)*	**156,512**	145,349
A[illegible] *(B)*	**50**	52
Total inpatient revenue *(RMB'000)*	**1,218,310**	1,053,686
Total average inpatient spending per bed-day *(RMB)*	**389**	380
Outpatients		
[illegible]	**527,050**	402,666
[illegible] *(B'000)*	**58,089**	54,071
A[illegible] *(B)*	**110**	134
[illegible] *(B'000)*	**148,606**	122,239
A[illegible] *(B)*	**282**	304
Total outpatient revenue *(RMB'000)*	**206,695**	176,310
Total average outpatient spending per visit *(RMB)*	**392**	438
Total treatment and general healthcare services revenue *(RMB'000)*	**1,119,887**	962,408
Total pharmaceutical sales revenue *(RMB'000)*	**305,118**	267,588

D[illegible] B[illegible] B1,218.3 [illegible] 15.6% [illegible] 2021, [illegible]: (i) [illegible] G[illegible] 13.0%, [illegible] K[illegible] H[illegible], K[illegible] H[illegible], K[illegible] H[illegible], [illegible] H[illegible], C[illegible] H[illegible], C[illegible] H[illegible], [illegible] H[illegible] J[illegible] H[illegible]; (ii) [illegible] G[illegible] 2.4%. [illegible] B[illegible] B[illegible] 85.5% (2021: 85.7%).

[illegible] B206.7 [illegible] 17.2% [illegible] 2021, [illegible] 30.9% [illegible] 10.5%. [illegible] 14.5% (2021: 14.3%).

[illegible] 16.4% [illegible] 2021, [illegible] 78.6% (2021: 78.2%) [illegible] 14.0% [illegible] 2021, [illegible] 21.4% (2021: 21.8%) [illegible] 12.8% (2021: 13.8%), [illegible] 71.9% (2021: 69.3%).

[illegible]:

	For the year ended December 31,	
	2022	2021
	(RMB'000)	*([illegible] B'000)*
[illegible]	**339,777**	310,090
[illegible]	**390,107**	321,207
[illegible]	**33,584**	42,283
[illegible]	**99,553**	75,386
[illegible]	**63,747**	53,470
[illegible]	**27,588**	25,595
[illegible]	**85,759**	69,081
Cost of revenue of owned hospitals	**1,040,115**	897,112

[illegible] B1,040.1 [illegible] 15.9% [illegible] 2021. [illegible] 9.6% [illegible] 21.5% [illegible] 32.1% [illegible] 2021.

F[illegible] 32.7% (2021: 34.6%). [illegible] 37.5% (2021: 35.8%). [illegible] 12.8% (2021: 13.1%).

[illegible]

[illegible] G[illegible] B110.0 [illegible] B85.5 [illegible] (2021: [illegible] B51.6 [illegible]).

[illegible]

[illegible] G[illegible] B8.1 [illegible] (2021: [illegible] B23.6 [illegible]), [illegible] H[illegible].

4.1.2 Gross Profit and Gross Profit Margin

D[illegible] G[illegible] B352.9 [illegible] 7.3% [illegible] 2021. [illegible] B326.7 [illegible] 6.9% [illegible] 2021. [illegible]:

	For the year ended December 31, 2022	2021
[illegible]	**27.4%**	29.6%
[illegible]	**11.6%**	10.7%
Owned hospitals businesses	**23.9%**	25.4%
[illegible]	**22.2%**	24.7%
Consolidated gross profit margin	**23.8%**	25.4%

D[illegible] G[illegible] 23.8% (2021: 25.4%), [illegible] 2.2 [illegible] 2021, [illegible] B43.6 [illegible]

4.1.3 Tax and Surcharge

D[illegible] G[illegible] B5.0 [illegible] (2021: [illegible]B5.8 [illegible]).

4.1.4 Selling Expenses

D[illegible] G[illegible] B15.0 [illegible] (2021: [illegible]B10.3 [illegible]). [illegible] 1.1% [illegible] G[illegible] (2021: 0.9%).

4.1.5 Administrative Expenses

D[illegible] G[illegible] G[illegible]:

	For the year ended December 31,	
	2022	2021
	(RMB'000)	*([illegible]B'000)*
E[illegible]	**111,252**	100,510
D[illegible]	**24,761**	22,117
C[illegible]	**29,187**	13,014
[illegible]	**4,359**	2,835
[illegible]	**36,328**	37,896
Total administrative expenses	**205,887**	176,372

D[illegible] G[illegible] B205.9 [illegible] 16.7% [illegible] 2021, [illegible] B13.5 [illegible] G[illegible] 15.1% (2021: 14.7%).

4.1.6 Research and Development Expenses

[illegible] Group's [illegible] :

	For the year ended December 31,	
	2022	2021
	(RMB'000)	*(RMB'000)*
C[illegible]	**18,899**	16,487
D[illegible]	**9,803**	8,059
C[illegible]	**4,053**	3,114
[illegible]	**273**	302
Total	**33,028**	27,962

D[illegible] Group's [illegible] RMB33.0 [illegible] (2021: RMB28.0 [illegible]), [illegible] 18.1% [illegible] 2021. [illegible] Group [illegible] 2.4% (2021: 2.3%), [illegible] Group.

4.1.7 Finance Expenses – Net

[illegible]

	For the year ended December 31,	
	2022	2021
	(RMB'000)	*([illegible]B'000)*
I[illegible]	**-2,762**	-1,691
F[illegible]	**-78**	39
B[illegible]	**33,214**	21,978
I[illegible]	**11,936**	14,290
[illegible]	**2,000**	3,042
Finance expenses – net	**44,310**	37,658

D[illegible] G[illegible] [illegible]B44.3 [illegible] B6.7 [illegible] 2021, [illegible] 51.1% [illegible] 2021, [illegible] G[illegible]. I[illegible] B2.4 [illegible] 2021.

4.1.8 Investment Income

[illegible]:

	For the year ended December 31,	
	2022	2021
	(RMB'000)	*([illegible]B'000)*
		([illegible])
[illegible]	**-15,927**	-6,566
G[illegible]	**18,063**	7,075
D[illegible]	**714**	6,429
	2,850	6,938

D[illegible] B2.9 [illegible], [illegible] H [illegible] H[illegible]. A[illegible] B-15.9 [illegible] H [illegible] H [illegible] H [illegible] A [illegible] I [illegible] C[illegible]., L[illegible].

4.1.9 Credit Impairment Losses

D[illegible] B25.2 [illegible] (2021: [illegible] B2.1 [illegible]), [illegible] G[illegible]' [illegible] H [illegible] H [illegible] B15.9 [illegible].

4.1.10 Asset Impairment Losses

D[illegible] B10.3 [illegible], [illegible] B [illegible] H [illegible] G[illegible].

4.1.11 Non-Operating Income and Non-Operating Expenses

[illegible]:

	For the year ended December 31,	
	2022	2021
	(RMB'000)	*([illegible]B'000)*
G[illegible]	**55**	266
D[illegible]	**7,436**	9,470
D[illegible]	**–**	1,800
[illegible]	**1,063**	300
Non-operating income	**8,554**	11,836
L[illegible]	**1,588**	166
D[illegible]	**3,928**	3,333
E[illegible]	**1,754**	1,399
E[illegible]	**–**	2,000
[illegible]	**2,071**	1,739
Non-operating expenses	**9,341**	8,637

D[illegible] B8.6 [illegible] B3.3 [illegible] 2021, [illegible] B9.3 [illegible] B1.4 [illegible] 2021.

4.1.12 Income Tax Expense

D[illegible] B26.6 [illegible] (2021: [illegible] B54.8 [illegible]), [illegible] 51.5% [illegible] 2021. I[illegible] 2022 [illegible] 2021, [illegible] 170.3% [illegible] 57.3%, [illegible].

4.2 Financial Position

4.2.1 Inventory

A[illegible] D[illegible] 31, 2022, [illegible] B58.3 [illegible] ([illegible] D[illegible] 31, 2021: [illegible] B56.5 [illegible]), [illegible].

4.2.2 Accounts Receivables

A[illegible] D[illegible] 31, 2022, [illegible] B382.8 [illegible] (D[illegible] 31, 2021: [illegible] B311.8 [illegible]), [illegible] 22.8% [illegible] D[illegible] 31, 2021, [illegible] G[illegible]'[illegible].

D[illegible], [illegible] G[illegible]'[illegible] 42 [illegible] (2021: 37 [illegible]).

4.2.3 Other Receivables and Prepayments

A f D 31, 2022, B69.4 (f D 31, 2021 (): B41.8).

4.2.4 Other Non-current Financial Assets

A f D 31, 2022, f - f B63.1 (f D 31, 2021: B65.8). D f f - f B2.7 , f f G ' J F .

4.2.5 Construction in progress

A f D 31, 2022, f B152.5 (f D 31, 2021: f B43.8), f L H , f L C H , f H f J H .

4.2.6 Right-of-use Assets

A f D 31, 2022, - f B190.4 (f D 31, 2021: B257.4), - f f B54.2 f f f H H G .

4.2.7 Accounts Payables

A f D 31, 2022, B85.8 (f D 31, 2021: B69.2).

4.2.8 Receipts in Advance and Contract Liabilities

A f D 31, 2022, B 29.9 (f D 31, 2021: B16.3).

4.2.9 Other Payables

A f D 31, 2022, B72.2 (f D 31, 2021 (): B57.3), f f B17.0 f L H .

4.3 Liquidity and Capital Resources

	For the year ended December 31, 2022 (RMB'000)	2021 (B'000)
	227,221	193,896
	-273,615	-239,049
	116,178	33,833
	69,861	-11,358

4.3.1 Net Cash Generated from Operating Activities

D B227.2 B-24.2 B35.5 B160.6 C B11.6

4.3.2 Net Cash Used in Investing Activities

D B273.6 B236.9 L H H L C H J H E H C H

4.3.3 Net Cash Generated from Financing Activities

D B116.2

4.3.4 Significant Investment, Acquisition and Disposal

G

A G B

4.4 Indebtedness

4.4.1 Bank Borrowings

A f D 31, 2022, f f G B616.5 (f D 31, 2021: B553.2), f f B339.4 f B402.7 .

4.4.2 Contingent Liability

A f D 31, 2022, G f f G .

4.4.3 Asset Pledge

G ' K H f , f L D 826751, f L D 826750, (2016) E 0010144, (2016) E 0010142, (2021) E 0081628, G (2015) 1-11836 G (2015) 1-11833, C CITIC B - f . A D 31, 2022, f B195.0 .

4.4.4 Lease Liabilities

G f f . A f D 31, 2022, f - , f f B25.5 B171.4 .

4.4.5 Financial Instruments

F f G f , - f , , , . C ' ff

4.4.6 Exposure to Fluctuation in Exchange Rates

G f f f , f f f HKD B. G f .

A f D 31, 2022, G f . C f f , f f .

4.4.7 Gearing Ratio

A f D 31, 2022, G ( ) 49.7% (f D 31, 2021 ( ): 46.2%), f .

4.4.8 Employees and Remuneration Policy

A f D 31, 2022, G f 4,196 f (f D 31, 2021: 3,661 f). D , (f f f) B529.4 (2021: B443.3). B124.3 (G). , f f .

4.4.8.1 I

I f f G , C f E I f 2018 f K H C ., L . (**Equity Incentive Scheme**), f C f 2017 J 13, 2018 (**2017 AGM**). I f f C A f , B f C , f E I f C I E I , J 24, 2021. f , f C 29, 2018, 30, 2018, 14, 2021, J 18, 2021 J 25, 2021.

I f E I , f f f 165 , 1,818,529 . f f f 23 , 180,516 . ( ) f f f 13 , 540,229 . A f f f 8 , f 79,274 . A f f , f E I 193 , 2,460,000 . f 3.2976% f f C f f . f 48 f f , B10.47/ .

5 SIGNIFICANT EVENTS

5.1 Dividend

B ... D ... 31, 2022.

5.2 Independent investigation related matters

C ... A ... 1, 2022, ... C ... LL (**PwC**), ... C ... (...) BD C ... L ... C ... A ... LL (**BDO**), ... C ... D ... 31, 2021.

C, ... C ... : (1) ... C ... ; (2) ... C ... ; (3) ... C ...

14, 2022, ... C ... (**Investigation Firm**) ... (1) ... (**Alleged Area I**); (2) ... C ... (**Alleged Area II**); (3) ... C ... (**Alleged Area III**). D ... 14, 2022 ... 23, 2022, ... I ... F ... 14, 2022. I ... C ... C ... C ... I ... F ... A ... A ... A ... C ...

C ... A ... A ... D ... 31, 2021 ... 2021 A ... 27, 2022 ... 15, 2022, ...

C ... I ... A ... J ... 30, 2022 ... I ... J ... 30, 2022 ... J ... 10, 2023 ... J ... 16, 2023, ...

C ... B ...

I , B C :

1. C B C ;

2. A G H A A III, C ;

3. ;

5.3 Correction of previous accounting errors

[illegible]

5.3.1 Reasons for and details of the correction of previous accounting errors

[illegible]

[illegible]

5.3.2 ***The cumulative impact of the correction of previous accounting errors in the financial statements for 2020 and 2021***

(1) C[illegible] I[illegible] 2020

([illegible]: B[illegible])

Items	After restatement	Cumulative effect of error correction	Before restatement
[illegible]	12,987,640	9,190,863	3,796,777
G[illegible]	83,509,118	9,190,863	74,318,255
[illegible]	52,846,923	9,190,863	43,656,060
[illegible]	64,961,025	9,190,863	55,770,162

(2) C[illegible] B[illegible] 2020

([illegible]: B[illegible])

Items	After restatement	Cumulative effect of error correction	Before restatement
[illegible]	63,465,824	-12,878	63,478,702
[illegible]	542,683,617	-12,878	542,696,495
[illegible]	2,161,261,775	-12,878	2,161,274,653
[illegible]	76,603,400	-9,203,741	85,807,141
[illegible]	606,077,103	-9,203,741	615,280,844
[illegible]	946,349,216	-9,203,741	955,552,957
[illegible]	214,856,099	9,190,863	205,665,236
[illegible]	1,122,247,550	9,190,863	1,113,056,686
[illegible]	1,214,912,559	9,190,863	1,205,721,695
[illegible]	2,161,261,775	-12,878	2,161,274,653

(3) C[illegible] F[illegible] 2021

([illegible]: B[illegible])

Items	After restatement	Cumulative effect of error correction	Before restatement
[illegible]	29,925,488	-12,878	29,938,366
[illegible]	609,602,623	-12,878	609,615,501
[illegible]	2,377,954,989	-12,878	2,377,967,867
[illegible]	57,319,524	-9,203,741	66,523,265
[illegible]	535,774,635	-9,203,741	544,978,376
[illegible]	1,097,675,868	-9,203,741	1,106,879,609
I[illegible]	6,937,845	-12,878	6,950,723
[illegible]	257,098,624	9,190,863	247,907,761
[illegible]	1,208,263,897	9,190,863	1,199,073,034
[illegible]	1,280,279,120	9,190,863	1,271,088,257
[illegible]	2,377,954,989	-12,878	2,377,967,867

Opinions of the Independent Non-executive Directors

[illegible]

Opinions of the Board

[illegible]

Opinions of the Supervisory Committee

[illegible]

Opinions of the Audit Committee

[illegible]

6 PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

[illegible]

7 REVIEW OF ANNUAL RESULTS

[illegible]

[illegible]

8 COMPLIANCE WITH CG CODE

[illegible]

[illegible]

9 COMPLIANCE WITH THE MODEL CODE

C ... C ... C ... D ... C ... H ... D ... C ... D ... C ... C ...

... A.3 ... C ... 30 ... (...) ... (**Black-out Period**). ... B.8 ... C ...

... C ... J ... 30, 2022 (**Interim Results**) ... J ... 10, 2023. I ... D ... 28, 2022, ... C ... D ... C ... ( ) ... I ... ; ( ) ... D ... C ... C ... B ... (... D ... 11, 2022 ... J ... 10, 2023).

J ... 5, 2023, ... C ... A ... G L ... (**Ms. Wang**), ... D ... 100,000 D ... C ... A ... G J ... C ... B13.28 ... D ... 19, 2022 (**Disposal**). ... D ... B ... D ... C ... A ... C ... B ... C ... D ... C ... C ... A.3 ... B.8 ... C ...

... C ... C ... D ... C ... :

(1) ... D ... C ... D (...) ... B ... ;

(2) ... D ... C ... C ... C ... ;

(3) ... D ... C ...

[illegible]

[illegible]

10 EVENTS AFTER THE REPORTING PERIOD

[illegible]

11 AUDITORS AND WORKING SCOPE

[illegible]

[illegible]

12 FINANCIAL REPORT

12.1 Accounting Policies

[illegible] A[illegible] B[illegible] E[illegible] B[illegible], [illegible] F[illegible] F[illegible] 15, 2006 [illegible] ([illegible] **the Accounting Standards for Business Enterprises** [illegible] **CAS**).

[illegible]

[illegible] **.Chang6**

12.2 Annual Consolidated Financial Information

[illegible]

12.2.1 Annual Consolidated Income Statement

([illegible])

Items	Year ended December 31, 2022	2021 ([illegible])
I. Total revenue	**1,484,903,042**	1,297,430,370
[illegible]	**1,484,903,042**	1,297,430,370
[illegible]	–	[illegible]
[illegible]	–	[illegible]
[illegible]	–	[illegible]
II. Total cost of sales	**1,435,161,134**	1,226,514,556
[illegible]	**1,131,971,943**	968,432,456
[illegible]	–	[illegible]
[illegible]	–	[illegible]
[illegible]	–	[illegible]
[illegible]	–	[illegible]
[illegible]	–	[illegible]
[illegible]	–	[illegible]
[illegible]	–	[illegible]
[illegible]	**4,960,286**	5,754,219
[illegible]	**15,004,028**	10,335,393
[illegible]	**205,887,172**	176,371,889
[illegible]	**33,027,988**	27,962,173
[illegible]	**44,309,717**	37,658,426
[illegible]	**45,149,998**	36,267,757
[illegible]	**2,761,765**	1,691,367

Items	Year ended December 31, 2022	2021 ([illegible])
A [illegible]: [illegible]	**14,907,711**	13,619,635
I [illegible] ([illegible] "-" [illegible])	**2,850,458**	6,937,845
I [illegible]: I [illegible]	**-15,926,847**	-6,565,720
D [illegible]	**–**	
F [illegible] ([illegible] "-" [illegible])	**–**	
G [illegible] ([illegible] "-" [illegible])	**–**	
G [illegible] ([illegible] "-" [illegible])	**-15,977,326**	9,417,391
C [illegible] ([illegible] "-" [illegible])	**-25,191,541**	-2,140,196
A [illegible] ([illegible] "-" [illegible])	**-10,345,461**	-6,179,290
G [illegible] ([illegible] "-" [illegible])	**406,185**	-79,404
III. Operating profit (losses represented with "–" signs)	**16,391,934**	92,491,795
A [illegible]: [illegible]	**8,553,978**	11,835,932
L [illegible]: [illegible]	**9,341,039**	8,636,584
IV. Total profit (total losses represented with "-" signs)	**15,604,873**	95,691,143
L [illegible]: I [illegible]	**26,573,712**	54,830,913
V. Net profit (net losses represented with "-" signs)	**-10,968,839**	40,860,230
(I) C [illegible]		
1. [illegible] ([illegible] "-" [illegible])	**-10,968,839**	40,860,230
2. [illegible] ([illegible] "-" [illegible])	**–**	
(II) C [illegible]		
1. [illegible] ([illegible] "-" [illegible])	**-24,220,782**	44,035,995
2. [illegible] ([illegible] "-" [illegible])	**13,251,944**	-3,175,765

Items	Year ended December 31, 2022	2021 ([illegible])
VI. Other comprehensive income, net of tax		
[illegible]		
(I) [illegible]		
1. C [illegible]	–	[illegible]
2. [illegible]	–	[illegible]
3. C [illegible]	–	[illegible]
4. C [illegible]	–	[illegible]
(II) [illegible]		
1. [illegible]	–	[illegible]
2. C [illegible]	–	[illegible]
3. A [illegible]	–	[illegible]
4. C [illegible]	–	[illegible]
5. [illegible]	–	[illegible]
6. E [illegible]	–	[illegible]
7. [illegible]	–	[illegible]
[illegible]	–	[illegible]
VII. Total comprehensive income	**-10,968,838**	40,860,230
A [illegible]	**-24,220,782**	44,035,995
A [illegible]	**13,251,944**	-3,175,765
VIII. Earnings per share:		
(I) B [illegible] ([illegible] B [illegible])	**-0.32**	0.61
(II) D [illegible] ([illegible] B [illegible])	**-0.32**	0.59

12.2.2 *Annual Consolidated Balance Sheets*

(A[illegible] B[illegible])

ASSETS	December 31, 2022	D[illegible] 31, 2021 ([illegible])	J[illegible] 1, 2021 ([illegible])
Current assets:			
C[illegible]	**271,094,963**	188,734,846	206,499,564
[illegible]	**–**		
[illegible]	**–**		
F[illegible]	**10,641,026**	10,000,000	
D[illegible]	**–**		
[illegible]	**–**		
A[illegible]	**382,836,691**	311,757,875	225,300,247
[illegible]	**–**		
A[illegible]	**32,201,224**	11,858,427	9,909,510
[illegible]	**–**		
[illegible]	**–**		
[illegible]	**–**		
[illegible]	**37,195,220**	29,925,488	63,465,824
F[illegible]	**–**		
I[illegible]	**58,331,397**	56,519,301	37,508,472
C[illegible]	**–**		
A[illegible]	**–**		
C[illegible]	**–**		
[illegible]	**752,325**	806,686	
Total current assets	**793,052,846**	609,602,623	542,683,617

ASSETS	**December 31, 2022**	D[illegible] 31, 2021 ([illegible])	J[illegible] 1, 2021 ([illegible])
Non-current assets:			
G[illegible]	**–**		
D[illegible]	**–**		
[illegible]	**–**		
L[illegible]	**14,000,000**		
L[illegible]	**143,546,246**	129,847,779	97,816,934
I[illegible] [illegible]	**–**		
[illegible]	**63,116,852**	65,812,275	57,404,918
I[illegible]	**–**		107,804,936
F[illegible]	**695,020,441**	721,846,772	533,743,384
C[illegible]	**152,497,400**	43,795,718	134,941,286
[illegible]	**190,403,752**	257,412,270	232,612,441
I[illegible]	**254,684,348**	227,991,785	162,536,728
D[illegible]			
G[illegible]	**107,655,738**	135,741,377	79,199,853
L[illegible]	**189,586,339**	150,501,038	153,550,840
D[illegible]	**20,682,398**	14,336,965	40,258,388
[illegible]	**13,541,047**	21,066,387	18,708,451
Total non-current assets	**1,844,734,561**	1,768,352,366	1,618,578,158
TOTAL ASSETS	**2,637,787,407**	2,377,954,989	2,161,261,775

LIABILITIES AND SHAREHOLDERS’ EQUITY	**December 31, 2022**	D[illegible] 31, 2021 ([illegible])	J[illegible] 1, 2021 ([illegible])
Current liabilities:			
[illegible]	**203,000,000**	254,050,000	312,500,000
B[illegible]	**–**		
[illegible]	**–**		
F[illegible]	**13,922,929**		
D[illegible]	**–**		
[illegible]	**997,944**		36,080
A[illegible]	**85,773,062**	69,162,002	71,955,864
[illegible]	**29,894,837**	16,275,603	4,644,278
C[illegible]	**–**	3,241	12,965,175
F[illegible]	**–**		
[illegible]	**–**		
F[illegible]	**–**		
F[illegible]	**–**		
E[illegible]	**70,588,350**	60,488,184	42,785,133
T[illegible]	**33,507,164**	30,235,329	49,046,555
[illegible]	**72,193,730**	57,319,524	76,603,400
F[illegible]	**–**		
[illegible]	**–**		
L[illegible]	**–**		
C[illegible]	**147,598,324**	48,240,752	35,540,617
[illegible]	**–**		
Total current liabilities	**657,446,340**	535,774,635	606,077,103

LIABILITIES AND SHAREHOLDERS' EQUITY	December 31, 2022	D[illegible] 31, [illegible] 2021 ([illegible])	J[illegible] 1, [illegible] 2021 ([illegible])
Non-current liabilities:			
[illegible]	–	[illegible]	[illegible]
[illegible]	**391,010,000**	280,950,000	110,992,970
[illegible]	–	[illegible]	[illegible]
[illegible]	–	[illegible]	[illegible]
[illegible]	–	[illegible]	[illegible]
[illegible]	**171,437,740**	231,733,760	194,601,230
[illegible]	**42,404,938**	[illegible]	[illegible]
[illegible]			
[illegible]	–	[illegible]	[illegible]
[illegible]	–	[illegible]	[illegible]
[illegible]	**9,037,891**	9,341,683	9,645,475
[illegible]	**40,547,879**	39,875,790	25,032,438
[illegible]	–	[illegible]	[illegible]
Total non-current liabilities	**654,438,448**	561,901,233	340,272,113
Total liabilities	**1,311,884,788**	1,097,675,868	946,349,216
Shareholders' equity:			
[illegible]	**74,600,300**	74,600,300	74,600,300
[illegible]	–	[illegible]	[illegible]
[illegible]	–	[illegible]	[illegible]
[illegible]	–	[illegible]	[illegible]
[illegible]	**855,078,533**	838,165,396	819,309,066
[illegible]	–	[illegible]	23,311,144
[illegible]	–	[illegible]	[illegible]
[illegible]	–	[illegible]	[illegible]
[illegible]	**38,399,577**	38,399,577	36,593,229
[illegible]	–	[illegible]	[illegible]
[illegible]	**233,506,534**	257,098,624	214,856,099
[illegible]	**1,201,584,945**	1,208,263,897	1,122,247,550
[illegible]	**124,317,674**	72,015,224	92,665,099
Total shareholders' equity	**1,325,902,619**	1,280,279,120	1,214,912,559
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**2,637,787,407**	2,377,954,989	2,161,261,775

12.2.3 *Annual Consolidated Statements of Cash Flow*

(A [illegible] B [illegible])

Items	Year ended December 31, 2022	2021
I. Cash flows from operating activities		
C[illegible]	**1,452,028,763**	1,211,114,151
[illegible]	**–**	[illegible]
[illegible]	**–**	[illegible]
[illegible]	**–**	[illegible]
C[illegible]	**–**	[illegible]
[illegible]	**–**	[illegible]
[illegible]	**–**	[illegible]
C[illegible]	**–**	[illegible]
[illegible]	**–**	[illegible]
[illegible]	**–**	[illegible]
[illegible]	**–**	[illegible]
[illegible]	**–**	[illegible]
C[illegible]	**100,857,821**	96,220,745
Sub-total of cash inflows of operating activities	**1,552,886,584**	1,307,334,896
C[illegible]	**613,477,475**	553,860,986
[illegible]	**–**	[illegible]
[illegible]	**–**	[illegible]
C[illegible]	**–**	[illegible]
[illegible]	**–**	[illegible]
C[illegible]	**–**	[illegible]
C[illegible]	**–**	[illegible]
C[illegible]	**525,082,523**	425,383,922
[illegible]	**51,200,498**	44,017,853
C[illegible]	**135,905,523**	90,175,636
Sub-total of cash outflows of operating activities	**1,325,666,020**	1,113,438,397
Net cash flows from operating activities	**227,220,564**	193,896,499

Items	Year ended December 31, 2022	2021
II. Cash flows from investing activities		
C[illegible]	**–**	52,119,176
C[illegible]	**1,650,804**	7,777,189
[illegible]	**24,100,367**	8,755,311
[illegible]		
C[illegible]	**–**	[illegible]
[illegible]	**25,751,171**	68,651,676
C[illegible]	**236,910,179**	178,536,614
C[illegible]	**–**	48,600,000
[illegible]	**–**	[illegible]
[illegible]	**53,685,701**	80,564,033
C[illegible]	**8,770,704**	[illegible]
Sub-total of cash outflows of investing activities	**299,366,584**	307,700,647
Net cash flows from investing activities	**-273,615,413**	-239,048,971

Items	Year ended December 31, 2022	2021
III. Cash flows from financing activities		
C[illegible]	**9,153,084**	2,900,000
I[illegible]: C[illegible] [illegible]	**9,153,084**	2,900,000
C[illegible]	**387,500,000**	550,250,000
C[illegible]	**151,420,250**	–
[illegible]	**548,073,334**	553,150,000
C[illegible]	**324,220,000**	428,342,970
C[illegible] [illegible]	**51,554,508**	30,297,107
I[illegible]: C[illegible] [illegible] [illegible]	**–**	–
C[illegible]	**56,121,295**	60,676,566
Sub-total of cash outflows of financing activities	**431,895,803**	519,316,643
Net cash flows from financing activities	**116,177,531**	33,833,357
IV. Effect of foreign exchange rate changes on cash and cash equivalents	**78,463**	-38,704
V. Net increase in cash and cash equivalents	**69,861,145**	-11,357,819
A[illegible]: C[illegible] [illegible]	**188,734,846**	200,092,665
VI. Cash and cash equivalents at the end of the period	**258,595,991**	188,734,846

12.2.4 Consolidated Statement of Changes in Shareholders' Equity

(A[illegible] B[illegible])

Items	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus reserve	Provision for general risk	Retained earnings	Subtotal	Non-controlling interests	Total owners' equity
	Amount for the current period													
	Equity attributable to owners of the parent company													
		Other equity instruments												
I. B[illegible]	74,600,300				838,165,396				38,399,577		257,098,624	1,208,263,897	72,015,224	1,280,279,121
[illegible]: C[illegible]														
C[illegible]														
B[illegible]														
II. B[illegible]	74,600,300				838,165,396				38,399,577		257,098,624	1,208,263,897	72,015,224	1,280,279,121
III. I[illegible]					16,913,137						-23,592,090	-6,678,953	52,302,450	45,623,497
(I) [illegible]											-24,220,782	-24,220,782	13,251,943	-10,968,839
(II) [illegible]					12,214,419							12,214,419	43,363,507	55,577,926
1. C[illegible]													43,363,507	43,363,507
2. C[illegible]														
3. A[illegible]					12,214,419							12,214,419		12,214,419
4. [illegible]														

	Amount for the current period													
	Equity attributable to owners of the parent company													
		Other equity instruments												
Items	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus reserve	Provision for general risk	Retained earnings	Subtotal	Non-controlling interests	Total owners' equity
(III) D [illegible]													-4,313,000	-4,313,000
1. [illegible]													–	
2. [illegible]													-4,313,000	-4,313,000
3. [illegible]														
4. [illegible]														
(I[illegible]) I [illegible]														
1. C [illegible]														
2. C [illegible]														
3. [illegible] ff [illegible]														
4. C [illegible]														
5. C [illegible]														
6. [illegible]														

	Amount for the current period													
	Equity attributable to owners of the parent company													
		Other equity instruments												
Items	Share capital	Preferred shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserve	Surplus reserve	Provision for general risk	Retained earnings	Subtotal	Non-controlling interests	Total owners' equity
([illegible]) [illegible]														
1. [illegible]														
2. [illegible]														
([illegible]) [illegible]					4,698,718						628,692	5,327,410		5,327,410
[illegible]. B[illegible] f [illegible]	74,600,300				855,078,533				38,399,577		233,506,534	1,201,584,944	124,317,674	1,325,902,618

Item														
I.	74,600,300				819,509,066	23,311,144			36,593,229		205,665,236	1,113,056,687	92,665,009	1,205,721,696
											9,203,741	9,203,741		9,203,741
II.	74,600,300				819,509,066	23,311,144			36,593,229		214,868,977	1,122,260,428	92,665,009	1,214,925,437
III.					18,656,330	-23,311,144			1,806,348		42,229,647	86,003,469	-20,649,785	65,353,684
(I)											44,035,995	44,035,995	-3,175,765	40,860,230
(II)					20,182,750							20,182,750	-17,474,020	2,708,730
1.					2,445,056							2,445,056	-17,474,020	-15,028,964
2.														
3.					17,737,694							17,737,694		17,737,694
4.														

Item														
(III) D[illegible]									1,806,348		-1,806,348			
1. [illegible]									1,806,348		-1,806,348			
2. [illegible]														
3. [illegible]														
4. [illegible]														
(IV) I[illegible]														
1. C[illegible]														
2. C[illegible]														
3. [illegible]														
4. C[illegible]														

[illegible]

[illegible]														
[illegible]														
1. [illegible]														
2. [illegible]														
[illegible]					-1,526,420	-23,311,144						21,784,723		21,784,723
[illegible]	74,600,300.00				838,165,396				38,399,577		257,098,624	1,208,263,897	72,015,224	1,280,279,121

12.3 Notes to the Consolidated Annual Financial Information prepared in accordance with the China Accounting Standard for Business Enterprises

12.3.1 Accounts receivable

The aging analysis of accounts receivables based on the billing date is as follows:

	December 31, 2022 *RMB*	D 31, 2021 *B*
1	**388,961,193**	303,910,574
1 2	**4,755,920**	9,812,859
2 3	**3,941,367**	4,259,870
3 4	**3,248,300**	3,140,407
4 5	**1,932,594**	
	402,839,374	321,123,710
L : f	**20,002,683**	9,365,835
T	**382,836,691**	311,757,875

Accounts receivable shown by classification of bad debt provisions

	December 31, 2022				
	Balance of carrying amount		Provision for bad debts		
	Amount	Proportion (%)	Amount	Percent of provision (%)	Book value
[illegible]	**18,221,976**	**4.52**	**12,514,143**	**68.68**	**5,707,833**
[illegible]:					
[illegible]	**18,221,976**	**4.52**	**12,514,143**	**68.68**	**5,707,833**
[illegible]	**384,617,398**	**95.48**	**7,488,540**	**1.95**	**377,128,858**
[illegible]:					
[illegible]	**384,617,398**	**95.48**	**7,488,540**	**1.95**	**377,128,858**
[illegible]	**402,839,374**	**100.00**	**20,002,683**	**5.0**	**382,836,691**

	[illegible] 31, 2021 ([illegible])				
	[illegible]		[illegible]		
	[illegible]	[illegible] (%)	[illegible]	[illegible] (%)	[illegible]
[illegible]	7,247,978	2.26	4,590,286	63.33	2,657,692
[illegible]:					
[illegible]	7,247,978	2.26	4,590,286	63.33	2,657,692
[illegible]	313,875,732	97.74	4,775,549	1.52	309,100,183
[illegible]:					
[illegible]	313,875,732	97.74	4,775,549	1.52	309,100,183
[illegible]	321,123,710	100.00	9,365,835	[illegible]	311,757,875

12.3.2 Accounts payable

[illegible]:

	December 31, 2022 RMB	D[illegible]31, 2021 [illegible]B
[illegible]	**84,193,739**	65,938,475
[illegible]	**1,161,389**	2,767,906
[illegible]	**71,969**	168,510
A[illegible]	**345,965**	287,111
[illegible]	**85,773,062**	69,162,002

12.3.3 Revenue and cost of sales

Analysis of revenue and cost of sales

	Year ended December 31, 2022		[illegible] D[illegible]31, 2021	
	Revenue	Cost	[illegible]	C[illegible]
[illegible]	**1,366,816,938**	**1,040,114,650**	1,202,774,378	897,111,636
[illegible]	**118,086,104**	**91,857,293**	94,655,992	71,320,820
[illegible]	**1,484,903,042**	**1,131,971,943**	1,297,430,370	968,432,456

Breakdown of revenue:

	Year ended December 31, 2022 Revenue	[illegible] December 31, 2021 [illegible]
[illegible]	**1,366,816,938**	1,202,774,378
[illegible]	**305,118,303**	267,588,282
[illegible]	**1,061,698,635**	935,186,096
[illegible]	**118,086,104**	94,655,992
[illegible]		
[illegible]	**85,464,736**	51,613,429
[illegible]	**3,000,000**	2,970,297
[illegible]	**8,067,969**	7,515,329
[illegible]	**–**	16,043,548
[illegible]	**21,553,398**	16,513,389
[illegible]	**1,484,903,042**	1,297,430,370

12.3.4 Expenses by nature

[illegible]

	Year ended December 31, 2022	2021
[illegible]	**538,910,495**	435,967,572
[illegible]	**417,971,255**	353,105,992
[illegible]	**–**	15,204,373
[illegible]	**53,029,785**	45,173,131
[illegible]	**38,189,336**	45,435,381
[illegible]	**22,991,164**	15,010,630
[illegible]	**46,397,647**	38,371,918
[illegible]	**17,904,619**	15,472,885
[illegible]	**66,553,544**	57,050,466
[illegible]	**29,928,936**	24,096,156
[illegible]	**23,086,081**	21,047,712
[illegible]	**27,657,239**	25,603,836
[illegible]	**28,302,685**	13,820,362
[illegible]	**6,366,300**	1,222,900
[illegible]	**3,526,993**	2,990,339
[illegible]	**5,332,488**	4,416,545
[illegible]	**8,492,201**	9,312,808
[illegible]	**12,214,419**	15,932,752
[illegible]	**39,035,944**	43,866,152
[illegible]	**1,385,891,131**	1,183,101,910

12.3.5 Credit impairment losses

	Year ended December 31, 2022	2021
L[illegible]	**11,260,563**	3,005,695
L[illegible]	**13,930,978**	-865,499
T[illegible]	**25,191,541**	2,140,196

12.3.6 Earning per Share

Basic earning per Share

	Year ended December 31, 2022	2021
C[illegible]	**-24,220,782**	44,035,995
[illegible] C[illegible]	**74,600,300**	72,140,300
B[illegible]	**-0.32**	0.61
I[illegible]: B[illegible]	**-0.32**	0.61
B[illegible]	**–**	[illegible]

Diluted earning per Share

D[illegible] ([illegible]) [illegible] C[illegible] ([illegible]):

	Year ended December 31, 2022	2021
C[illegible] ([illegible])	**-24,220,782**	44,035,995
[illegible] C[illegible] ([illegible])	**74,600,300**	74,600,300
D[illegible]	**-0.32**	0.59
I[illegible]: D[illegible]	**-0.32**	0.59
D[illegible]	**–**	[illegible]

12.3.7 Income tax expenses

Table of income tax expenses

	Year ended December 31, 2022	2021
C[illegible]	**40,192,565**	26,919,820
D[illegible]	**-13,618,853**	27,911,093
T[illegible]	**26,573,172**	54,830,913

Reconciliation between total profit and income tax expenses

	Year ended December 31, 2022	2021 ([illegible])
T[illegible]	**15,604,874**	95,691,143
I[illegible]	**3,028,480**	21,762,976
I[illegible]	**7,125,277**	1,508,267
A[illegible]	**-3,896,947**	-2,591,474
I[illegible]	**-5,563,847**	-283,550
I[illegible]	**1,736,913**	4,012,268
I[illegible]	**137,339**	-3,047,922
I[illegible]	**31,726,873**	40,749,555
A[illegible]	**-4,141,335**	-3,263,746
I[illegible]	**-2,298,769**	-4,286,812
[illegible]	**-1,280,272**	271,351
I[illegible]	**26,573,712**	54,830,913

12.3.8 ***Dividend***

31, 2023, B D 31, 2022. AG .

26, 2022, B D 31, 2021. 2021 C D 16, 2022.

13 CONTINUED SUSPENSION OF TRADING

A f C , f C H K E 9:00 . A 1, 2022. f C .

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

14 DEFINITIONS

AG	f C f 2022
A C	f B
B H	B H C ., L . (北京怡寧醫院有限公司), C A 17, 2015, f C ’ -
B	f f C
C K H	C K H C ., L . (蒼南康寧醫院有限公司), C J 15, 2012, f C ’ -
C ’ K H	C ’ K H f H C ., L . (淳安康寧黃鋒醫院有限公司), C A 16, 2020, f C ’ -
C K H	K H C ., L ., C, H f B f E f H K L (C : 2120)
CG C	C G C A 14 H K L
D ( )	( ) f C
D ( )	( ) f C , f B1.00 , f B
G	C

H K H	H K H C ., L . (淮南康寧醫院有限公司), C 22, 2017, C
J H	J H C ., L . (浙江傑翎健康科技有限公司) (H I C ., L . (杭州耶利米信息科技有限公司)), C D 27, 2018, C
J H	J H C ., L . (縉雲舒寧醫院有限公司), C F 15, 2019, C
J F	C J H C I E I F (L. .) (重慶金浦醫療健康服務產業股權投資基金合夥企業(有限合夥)), C 22, 2016 C 3.5461% J F
L H	L H C ., L . (溫州鹿城怡寧醫院有限公司), C A 2, 2020, C
L C H	L C H C ., L . (臨海慈寧醫院有限公司), C D 11, 2020, C
C	C D L I A 10 H K L
H	H C ., L . (南京怡寧醫院有限公司), C J 22, 2018, C
C H	C H C ., L . (平陽長庚怡寧醫院有限公司), C J 14, 2021, C
H	H H C ., L . (浦江怡寧黃峰醫院有限公司), C 3, 2018, C

C C f C , f f

H K ,

A f C

H H C ., L (衢州怡寧醫院有限公司),

C

20, 2015, f C

K K H C . L . (青田康寧醫院有限公司),

H C A

1, 2011, f C

B f f C

( ) ( ) f C ,

f B1.00 , D ( )

H ( )

( ) ( ) f ( )

H (深圳怡寧醫院,

H H C ., L (深圳市怡寧醫院有限公

司)), C

22, 2014, f C

C

(C 622 f f H K)

D 31, 2022

K K H C ., L . (台州康寧醫院有限公

H 司), C

J 30, 2016, f C

C C H C . L . (溫州慈寧醫院有限公司),

H C J

25, 2006, f C

H C., L. (溫嶺南方精神疾病專科醫院有限公司), J 20, 2018, C

E H C., L. (溫州甌海怡寧老年醫院有限公司), 8, 2021, C

I H C., L. (怡寧心理互聯網醫院(溫州)有限公司), 10, 2020, C

K H C., L. (永嘉康寧醫院有限公司), D 12, 2012, C

K H C., L. (樂清康寧醫院有限公司), 3, 2013, C

I C H C., L. (樂清怡寧中西醫結合醫院有限公司), A 4, 2006, C, B C & H L (樂清邦爾中西醫結合醫院有限公司)

%

B B

Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
C

C
A 14, 2023

A C D G A G L D I H LI C D H G LI